| Autor: |
Yuen-Chin Ong, Hsiao-Wen Kao, Wen-Yu Chuang, Yu-Shin Hung, Tung-Liang Lin, Hung Chang, Ming-Chung Kuo |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Biomedical Journal, Vol 44, Iss 4, Pp 479-488 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2319-4170 |
| DOI: |
10.1016/j.bj.2020.04.005 |
| Popis: |
Background: Intravascular large B-cell lymphoma (IVLBCL) is a rare subtype of non-Hodgkin lymphoma with uncommon clinical presentations and poor prognosis. The purpose of this study is to report the clinical features and outcome of IVLBCL in a single institution of Taiwan. Methods: Ten patients with IVLBCL diagnosed from June 2006 to January 2018 were retrospectively reviewed. Results: The median age was 61 (range 39–88) years. The most common presentation was fever (90%), cytopenia (90%), and confusion (50%). For all patients, the median progression free survival (PFS) and overall survival (OS) were 12.6 (95% confidence interval [CI] 0.0–76.1) and 18.8 (95% CI 0–59.3) months, respectively. Six patients received rituximab combined chemotherapy, and the other one patient was treated with chemotherapy alone. Six of seven (85.7%) patients achieved complete response after chemotherapy. The median PFS and OS for six patients who completed treatment were not reached. Three-year PFS and OS rates were 80% and 75%, respectively. Conclusion: Our study showed that patients might achieve durable remission after rituximab-based chemotherapy. The outcome of IVLBCL patients may further improve if early diagnosis and prompt treatment were made. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
